{
    "nctId": "NCT06176339",
    "briefTitle": "Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients\"",
    "officialTitle": "\"Assessing the Clinical Utility of Adding Pentoxifylline to Neoadjuvant Chemotherapy Protocols in Breast Cancer Patients\"",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer Female",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 70,
    "primaryOutcomeMeasure": "Relative reduction in tumor size after neoadjuvant chemotherapy treatment",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult female patients \\>18 years old with histologic confirmation of invasive breast cancer\n* Planned to administer neoadjuvant chemotherapy protocol comprised of doxorubicin/ cyclophosphamide followed by paclitaxel (AC/T)\n* Adequate hepatic, renal, and bone marrow functions\n\nExclusion Criteria:\n\n* Patients on treatment regimen of phosphodiesterase inhibitors\n* Patients who are taking antiplatelet or anticoagulant treatment\n* Patients who are allergic to phosphodiesterase inhibitors\n* History of recent hemorrhagic events\n* Active peptic ulcer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}